Abstract
The aim of the present study was to evaluate correlations between serum osteocalcin, osteoprotegerin and NTX (Cross-linked N-telopeptides of Type I Collagen) and urinary NTX in breast and lung cancer patients with bone metastases. These four markers are considered to have important roles in bone formation, resorption and metastases. Four markers were determined in the sera of 60 breast cancer and 21 lung cancer patients and healthy controls (n=30). Serum levels were studied using ELISA and EIA. The median levels of serum osteoprotegerin (p<0.001) and osteocalcin (p=0.003) were higher in patients. Significant correlations were observed between the serum NTX-osteocalcin (r=0.431; p<0.001), serum NTX- osteoprotegerin (r=0.42; p=0.003) and serum NTX - urine NTX (r=0.255; p=0.022). We conclude that osteocalcin, osteoprotegerin and NTX are independent diagnostic tools. Due to the ease of urine collection, urine NTX may be applied routinely to allow early detection of bone metastases and indicate progression of the disease.
Highlights
Metastatic spread of cancer to bone is a prevalent extension of many malignancies
Significant correlations were observed between the serum NTX-osteocalcin (r=0.431; p
81 patients who had histologically confirmed breast (n=60; 60 women) and lung cancer (n=21; 16 men, 5 women) associated with scintigraphic evidence and radiographic confirmation of bone metastases were included in the study consecutively admitted to the Istanbul University, Oncology Institute during one-year period, January 2011 to December 2011
Summary
Metastatic spread of cancer to bone is a prevalent extension of many malignancies. Over one-fourth of all cancer patients demonstrate some degree of metastatic disease to bone. Patients with breast and prostate cancer are at risk for metastatic bone disease: >75% of these patients may have bone metastases of their primary malignancy (Roodman, 2012). Oncologists have traditionally relied on bone scan and (or) bone survey to detect disease dissemination. These methods, quite specific, are relatively insensitive in detecting early metastatic lesions to bone. The recent development of relatively sensitive and specific biochemical markers of bone turnover (Kamiya et al, 2012) has generated interest in the potential use of these markers for the early detection of bone metastases, and their use in assessing the efficacy and response to antiresorptive medications lended assistance for treating patients with metastatic bone disease (Johansen et al, 2007; Jung et al, 2011)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
